Background: Inflammatory bowel disease (IBD) occurs more frequently in patients with psoriasis. The 2 diseases have significant genetic overlap, but the pathogenesis underlying their co-occurrence is unknown.
Objective: We sought to report adjudicated IBD cases (Crohn's disease [CD] and ulcerative colitis [UC] ) in patients exposed to ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A.
Methods: Adverse events (AEs) integrated from 7 randomized controlled and uncontrolled trials were analyzed for the controlled induction period, controlled maintenance period, and all ixekizumab-treated patients. Suspected IBD cases were reviewed by blinded external experts using internationally recognized criteria (Registre Epidemiologique des Maladies de l'Appareil Digestif registry).
Results: In all, 4209 patients (6480 patient-exposure years) were exposed to ixekizumab. Suspected CD (N = 12) or UC (N = 17) AEs were reported; 19 were adjudicated as definite/probable IBD (CD, N = 7, incidence rate = 1.1/1000 patient-exposure years; UC, N = 12, incidence rate = 1.9/1000 patient-exposure years). Among these, 3 occurred during induction (CD, N = 1; UC, N = 2) and 7 during maintenance (CD, N = 4; UC, N = 3). Twelve of 16 patients with reported IBD history have not had an IBD treatment-emergent AE/serious AE to date.
Limitations: Clinical review (adjudication) was not prespecified. AE data collected post-hoc may have been limited by length of time from occurrence.
Conclusion: From an integrated database of 7 ixekizumab psoriasis trials, CD and UC cases were uncommon (\1%). ( J Am Acad Dermatol 2017;76:441-8.)
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Plaque psoriasis is an immune-mediated inflammatory skin disease with increased risks for other inflammatory conditions such as inflammatory bowel disease (IBD). Although the exact pathogenesis underlying co-occurrence of psoriasis and certain comorbidities is unknown, similarities in genetic risk and shared inflammatory cytokines have been highlighted as potential risk factors. Crohn's disease (CD) and ulcerative colitis (UC) are the 2 most common forms of IBD and are characterized by chronic and recurrent intestinal inflammation. Several studies have demonstrated increased CD and UC prevalence among patients with psoriasis. [1] [2] [3] [4] In 1 epidemiologic study, patients with psoriasis were 2.5 times more likely to have CD and 1.6 times more likely to have UC. 5 Psoriasis and IBD share several characteristics in their inflammatory pathways. Cytokines, such as interleukin (IL)-23 and tumor necrosis factor, and T-helper 17 cells may be involved in both conditions. 6, 7 Earlier research in animal models suggested IL-17 involvement in the pathogenesis of CD, 6 whereas IL-17 was protective against IBD in murine models, 8 and a human study showed IL-17 overexpression in intestinal tissue from patients with active CD. 9 In clinical trials of CD, both brodalumab (IL-17R antagonist) and secukinumab (IL-17A antagonist) failed to achieve the primary efficacy end point and in some cases CD worsened versus placebo while higher adverse event (AE) rates were also observed. 10, 11 In this context, during ongoing phase-III trials in patients receiving ixekizumab, a monoclonal antibody selectively targeting IL-17A, an independent external committee was established to adjudicate all potential AEs of IBD reported in an integrated database of 7 ixekizumab clinical trials in 4209 patients with moderate to severe psoriasis.
CAPSULE SUMMARY d
Patients with psoriasis have an increased incidence of inflammatory bowel disease; the 2 diseases have significant genetic overlap. From an integrated database of 7 ixekizumab psoriasis trials, cases of Crohn's disease and ulcerative colitis were uncommon (\1%).
Here we report the adjudicated CD and UC incidence using internationally recognized diagnostic criteria. This report provides more information than previously reported nonadjudicated, suspected IBD cases through 60 weeks in 3 phase-III ixekizumab trials in patients with moderate to severe psoriasis. 12 Furthermore, this work provides more data on IL-17A inhibition and IBD.
METHODS

Trial design and integrated data
Treatment-emergent AEs (TEAEs) and serious AEs (SAEs) through April 9, 2015, were integrated from 7 randomized controlled and uncontrolled trials (UNCOVER-1, UNCOVER-2, UNCOVER-3, UNCOVER-A, UNCOVER-J, a phase-I study, and a phase-II study) of ixekizumab in patients with moderate to severe plaque psoriasis (Table I) . [12] [13] [14] [15] [16] [17] [18] The all-ixekizumab analysis included all patients from these 7 studies who had 1 or more ixekizumab doses. UNCOVER-1, -2, and -3 were phase-III randomized controlled studies each with a 12-week induction period (placebo; 80-mg ixekizumab every 2 or 4 weeks; or, in UNCOVER-2 and -3, etanercept) and a randomized withdrawal maintenance period from week 12 to 60 for UNCOVER-1 and -2 (80-mg ixekizumab every 4 or 12 weeks, or placebo). [12] [13] [14] The phase-I, 6-week and the phase-II, 16-week double-blind studies both evaluated various ixekizumab doses. The phase-II study also examined 80-mg ixekizumab every 4 weeks. 15, 16 UNCOVER-A, 17 an open-label study, evaluated the pharmacokinetics of 80-mg ixekizumab every 4 weeks administered by prefilled syringe or autoinjector. UNCOVER-J was a 12-week open-label study of 80-mg ixekizumab every 2 weeks (induction) and 4 weeks (maintenance) in Japanese patients with psoriasis. 18 Eligibility criteria were similar across studies. [12] [13] [14] [15] [16] [17] [18] Patients (age $18 years) had a psoriasis diagnosis 6 months or longer before randomization, were candidates for phototherapy and/or systemic therapy, and had 10% or more body surface area, a static physician global assessment score 3 or greater (0-5 scale, higher scores indicate more severity), and a Psoriasis Area and Severity Index score 12 or greater (0-72 scale, higher scores indicate more severity) at both screening and baseline.
Patients with phenotypes other than plaque psoriasis (except in UNCOVER-J), or unstable psoriasis defined by investigator as a recent significant flare, were excluded. Use of medications that might confound efficacy was not allowed. In the UNCOVER-2 and -3 studies, patients who had used etanercept at any time before screening were excluded. 12 Detailed summaries of treatments permitted in the ixekizumab clinical trials are described elsewhere.
12-18 IBD history was neither an inclusion nor exclusion criterion. All patients gave informed written consent for all studies. Individual protocols received ethical review board approval. Clinicaltrials. gov numbers are NCT01474512, NCT01597245, NCT01646177, NCT01107457, NCT01777191, and NCT01624233.
Three safety cohorts of integrated data from the 7 studies were analyzed: (1) induction period: patients from the 12-week induction period of placebo-controlled (UNCOVER-1, -2, and -3) and etanercept-controlled (UNCOVER-2 and -3) studies; (2) maintenance period: patients from the 12-to 60-week maintenance periods of placebo-controlled UNCOVER-1 and -2 studies who were week-12 static physician global assessment score 0,1 ixekizumab responders (maintenance period ended if patient relapsed [ie, static physician global assessment score $3]); and (3) all ixekizumab treatment periods: all patients who received any ixekizumab dose during any period of any study up to 256 weeks.
IBD identification
At baseline, patients self-reported personal or family IBD history. Study sites reported all TEAEs/ SAEs of suspected IBD using narrow Medical Dictionary for Regulatory Activities preferred terms. Suspected CD terms were: ''Crohn's disease,'' ''anal abscess,'' ''anal fistula,'' ''perirectal abscess,'' and ''rectal abscess.'' Suspected UC terms were: ''colitis,'' ''colitis ulcerative,'' ''proctitis hemorrhagic,'' ''proctitis ulcerative,'' and ''pseudopolyposis.'' Additional follow-up was implemented to collect more information on each case. Cases were adjudicated by a committee of 3 independent, US-based gastroenterologists identified as IBD experts. All information pertaining to IBD-related TEAEs or SAEs was sent in blinded fashion to each adjudicator. Adjudication of IBD events was not prespecified; thus, this report is a post-hoc analysis. Adjudication criteria for IBD analysis An internationally recognized classification system combining reviews of radiographic, endoscopic, pathological, clinical, and laboratory features was used to classify a patient's likelihood of having CD or UC. 19 Adjudicators individually reviewed suspected IBD cases and reported findings as definite, probable, or possible using the Registre Epidemiologique des Maladies de l'Appareil Digestif (EPIMAD) registry methodology. 19 Two other categories included ''not consistent with IBD'' or ''not enough information to adjudicate.'' Adjudicators were not shown others' results until the process was complete. If an outcome was inconsistent across adjudicators (2 cases), those cases were re-reviewed by the committee chair for a final decision. Consistent with EPIMAD registry methods, only patients with definite or probable CD or UC were classified as having IBD. b Patient was on 80-mg IXE Q4W during the induction period (after a 160-mg starting dose) then discontinued because of pregnancy ande69 days after discontinuing treatmentereported a flare of UC. CD, Crohn's disease; DC, discontinued; ETN, etanercept; Hx, history; IBD, inflammatory bowel disease; IXE, ixekizumab; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; Q12W, every 12 weeks; SAE, serious adverse event; TEAE, treatment-emergent adverse event; UC, ulcerative colitis. 
RESULTS
Overall results
Overall, 4209 patients were exposed to any ixekizumab dose in the 7 ongoing and completed trials and comprised the overall safety population (Fig 1) . The follow-up was up to 256 weeks, comprising 6480 patient-exposure years. Baseline demographics are listed in Table II . In all, 24% were smokers in this psoriasis population.
From the overall safety population, 29 patients reported suspected CD (N = 12) or UC (N = 17) (Fig 1) . Nineteen (19/4209 [0.5%]) were adjudicated as definite or probable: CD (n = 7) or UC (n = 12). The exposure-adjusted incidence rate for CD was 1.1/1000 patient-exposure years and for UC was 1.9/1000 patient-exposure years (Table III) . In total, 5 of the 7 patients with probable or definitive CD, and 6 of the 12 patients with probable or definitive UC discontinued secondary to TEAE/SAE of IBD. One additional patient with suspected UC discontinued secondary to pregnancy and another because of protocol violation.
Induction period
During induction, 2 patients receiving 80-mg ixekizumab every 2 and 4 weeks were reported to have suspected CD-related TEAE/SAEs, 1 of which was adjudicated as probable after 64 days of exposure ( Supplemental Fig 1; available at http:// www.jaad.org) and the other was adjudicated as possible after 88 days of exposure. Two additional patients receiving 80-mg ixekizumab every 2 weeks were reported and adjudicated as definite UC after 14 and 62 days of treatment (Supplemental Fig 2; available at http://www.jaad.org).
Maintenance period
In total 8 patients were reported to have a TEAE/SAE of IBD during the UNCOVER-1 and -2 maintenance periods, all of whom had exposure to ixekizumab. Five had suspected CD-related TEAE/ SAEs, of which 4 were adjudicated as definite or probable. One of the 4 patients was on ixekizumab for 353 days at the time of the event and 3 were on placebo, but had been on ixekizumab during the induction period ( Supplemental Fig 1) . Three patients had UC-related TEAE/SAEs during the maintenance period, of which all 3 were adjudicated as definite or probable, with an average ixekizumab exposure of 274 days (Supplemental Fig 2) .
All ixekizumab analysis set (excluding induction or maintenance)
Besides events reported during induction and maintenance, 17 patients reported suspected CD (N = 5) or UC (N = 12), of which 9 patients were adjudicated as definite or probable: CD (N = 2) or UC (N = 7). Among these 9, 1 patient with UC experienced the event 69 days after discontinuing ixekizumab. For the 2 patients with CD adjudicated as definite or probable, average ixekizumab exposure was 207 days, and for the 7 patients with UC, average ixekizumab exposure was 178 days. One patient with CD had the event adjudicated as possible during the induction period and experienced a second event during the maintenance period, which was adjudicated as definite.
IBD flares versus new onset
A total of 16 patients from the 7 trials reported IBD history. Four of these patients had TEAE/SAE of suspected IBD; all were adjudicated as IBD (1 CD, 3 UC). The remaining 12 have not had a TEAE/SAE of IBD to date.
Of the 19 patients adjudicated as having an IBD-related TEAE/SAE, 4 experienced flares and the remaining 15 (CD, N = 6; UC, N = 9) represent new cases. One patient with a history of CD experienced a flare. This patient's pre-existing CD was not captured in the database as the history was not elucidated by a gastroenterologist until after the definitive event.
Three patients with pre-existing UC experienced a flare after a mean of 180 days of ixekizumab exposure.
Exposure to ixekizumab
Of note, the overall exposure time to ixekizumab (6480 patient-exposure years) was significantly higher (;38 times longer) compared with etanercept exposure (169 patient-exposure years) and placebo exposure (180 patient-exposure years). An extrapolation of time to an IBD event, assuming a constant rate and no treatment differences, would lead to an anticipated 1 case in both nonixekizumab exposure arms together.
DISCUSSION
In light of emerging animal and human data suggesting a potential role for IL-17 in IBD, 6, 8, 9, 11 we undertook this adjudication analysis to gain greater understanding of IBD incidence in patients with moderate to severe psoriasis treated with ixekizumab, a high-affinity monoclonal antibody that selectively targets IL-17A. The findings suggest that new CD and UC cases during ixekizumab exposure were uncommon (\1%); flares of preexisting disease were also uncommon. Nevertheless, all CD and UC cases reported in the 7 trials for psoriasis had exposure to ixekizumab. Of note, some cases were exposed to etanercept before the switch to ixekizumab. Given the significantly greater exposure to ixekizumab than to etanercept or placebo, the number of IBD cases would be expected to be greater with ixekizumab than etanercept or placebo.
A limitation of this report is the post-hoc nature of the adjudication, which may have limited the data collection necessary for IBD confirmation. Also, the case report forms lacked specific questions regarding patient and family IBD history. Clinical and scientific interest in exploring the role of IL-17A inhibition and IBD emerged after the initiation of these studies. Investigators may not have routinely asked about IBD history in the absence of a required data point.
A strength of this report is the use of EPIMAD criteria, which are considered diagnostic and are accepted for reporting IBD incidence. 19 These standardized criteria are universal and not subject to differences in clinical interpretation. Despite this strength, the rigor assigned to the definition of ''definite'' disease may have led to fewer diagnoses in this category, although most would have been captured as ''probable'' IBD, and thus, counted as an adjudicated event.
The IBD incidence rates in patients treated with ixekizumab before adjudication are comparable with those in observational studies in psoriasis populations. Among Danish adults (total cohort, n = 5,554,100), there were 75,209 incident psoriasis cases, 11,309 incident CD cases, and 30,310 incident UC cases. 4 Adjusted incidence rates of CD ranged from 1.3 to 2.9 in 1000 patients in those with mild to severe psoriasis. The 10-year incidence was 2 to 5 in 1000 patients for CD and 7 to 11 in 1000 patients for UC, depending on psoriasis severity and presence of psoriatic arthritis; an increased risk of incident psoriasis was found after CD or UC. Similarly, the Nurses' Health studies I and II reported a significantly increased risk of CD with a multivariate adjusted relative risk of 4.00 (Nurses' Health study I) and 3.76 (Nurses' Health study II) in women with psoriasis compared with the general population. 20 Furthermore, Cohen et al 3 reported the prevalence of CD as: odds ratio 2.49 (95% confidence interval 1.71-3.62) and UC as: odds ratio 1.64 (95% confidence interval 1.15-2.33), and Augustin et al 21 reported CD (prevalence ratio, 2.1) and UC (prevalence ratio, 2.0) among the most frequent comorbidities in patients with psoriasis in Germany.
Interestingly, our patients with CD were older than those reported in a European study (median age in current study, 44.0 vs 26.5 years) as was the median age of patients with UC (42.0 vs 34.3 years). 19 Also, the majority of events in this report occurred in women. These differences may reflect distinct population characteristics in randomized clinical trials versus real-world observational registry data in patients with psoriasis. Also, although prior studies have found an association between smoking and increased risk of CD, 22, 23 the small number of smokers among our suspected IBD cases prevents any conclusion regarding its effect. Previously it has been suggested that patients might experience an IBD flare between 12 and 24 months after cessation of systemic biologics and systemic nonbiologic therapy. 24, 25 IBD waxes and wanes in severity and the reported prevalence of flares is wide ranging (12%-68% in CD and 9%-60% in UC) 26, 27 ; thus, in patients with reported IBD history, disease flares related to the pathophysiology of IBD is not uncommon. No conclusions can be made about a potential relationship between cessation of prior systemic medication and IBD from the current analysis because of limited information on duration of earlier therapies and presence of IBD symptoms before exposure to ixekizumab.
Although a potential causal relationship between IL-17 inhibition and IBD in patients with psoriasis is not established, new studies in animals have explored the potential contrasting effect of IL-17 inhibition. 6, 8 In this context, it is appropriate to advise dermatologists to monitor patients closely when using IL-17 inhibition in patients with concomitant psoriasis and IBD. Aligned with this recommendation, IL-17A antagonists used to treat psoriasis have warnings and precautions when prescribed to patients with IBD. 28 However, it is important to note that a direct comparison between different clinical trials is difficult if not unfeasible, as diagnostic criteria of IBD may have differed from trial to trial.
To date, current information from a large, safety database of ixekizumab clinical trials suggests that incidences of both CD and UC have been uncommon (\1%). The rates appear to be similar to the background IBD incidence reported in patients with psoriasis. 4 Further, among the 16 patients from the 7 trials who reported IBD history, 12 have not yet had a TEAE/SAE of IBD, suggesting that flares do not occur in the majority of patients with a history within the exposure time achieved to date.
Moving forward, ongoing and future ixekizumab trials include a comprehensive data-collection process that will provide greater detail for evaluation of potential IBD cases. This continued vigilance and postmarketing surveillance will help improve understanding of IBD incidence rates during treatment with this IL-17A antagonist. Supplemental Fig 1. Crohn's disease. Treatment sequence and exposure days before the first event.
